• LAST PRICE
    0.4905
  • TODAY'S CHANGE (%)
    Trending Down-0.0195 (-3.8325%)
  • Bid / Lots
    0.4581/ 1
  • Ask / Lots
    0.5030/ 5
  • Open / Previous Close
    0.4277 / 0.5100
  • Day Range
    Low 0.4277
    High 0.5100
  • 52 Week Range
    Low 0.4277
    High 2.3500
  • Volume
    42,158
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.51
TimeVolumeAPM
09:44 ET2000.4277
09:53 ET1000.499999
10:20 ET1000.5
10:24 ET23100.479999
10:26 ET83920.4789
10:27 ET63990.479493
12:15 ET32760.49
12:21 ET1000.4904
01:08 ET6000.49915
01:18 ET1000.4901
01:20 ET5000.49
01:22 ET15000.4902
01:26 ET35000.4803
01:29 ET15000.4581
01:54 ET5000.477073
02:12 ET1000.5032
02:14 ET5660.5033
02:16 ET1250.5033
02:18 ET1000.5032
03:08 ET2000.490454
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAPM
Aptorum Group Ltd
17.5M
-1.6x
---
United StatesCYTH
Cyclo Therapeutics Inc
15.9M
-1.1x
---
United StatesTTNP
Titan Pharmaceuticals Inc
14.3M
-1.1x
---
United StatesWSHE
Greenlink International Inc
19.0M
-4.8x
---
United StatesLEXX
Lexaria Bioscience Corp
17.4M
-2.4x
---
United StatesWPHM
Winston Pharmaceuticals Inc
23.2M
-8.2x
---
As of 2022-12-10

Company Information

Aptorum Group Limited is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The Company's segments include Therapeutics and Non-Therapeutics. Therapeutics segment is seeking to develop various drug molecules (including projects seeking to use extracts or derivatives from natural substances to treat diseases) and certain technologies for the treatment of human disease conditions to tackle unmet needs, in particular, two of its lead projects targeting infectious disease and cancer (including orphan oncology indications). Non-Therapeutics segment encompasses three businesses, such as diagnostics projects, including a molecular-based rapid pathogen identification and detection diagnostics (RPIDD) technology, natural supplements, including NativusWell, and AML Clinic.

Contact Information

Headquarters
17 Hanover SquareLONDON, United Kingdom W1S 1BN
Phone
208-092-9299
Fax
203-928-8277

Executives

President, Executive Director
Darren Lui
Chief Executive Officer, Founder, Executive Director
Ian Huen
Chief Financial Officer
Sabrina Khan
Chief Medical Officer and Executive Director
Clark Cheng
Head of Research and Development
Thomas Lee

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$17.5M
Revenue (TTM)
$1.4M
Shares Outstanding
35.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.02
EPS
$-0.30
Book Value
$0.66
P/E Ratio
-1.6x
Price/Sales (TTM)
12.2
Price/Cash Flow (TTM)
---
Operating Margin
-1,269.22%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.